Optimi Health Prices $15 Million Public Offering for Nasdaq Uplisting, Aims to Scale Psychedelic Drug Production
Optimi Health Corp. has priced a $15 million public offering as it uplists to the Nasdaq Capital Market, planning to use proceeds to expand production and distribution of its GMP-grade psychedelic drug products for mental health therapies.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) has announced the pricing of its underwritten public offering in connection with its uplisting to the Nasdaq Capital Market. The offering consists of 2.4 million common shares at US$6.25 per share, with expected gross proceeds of approximately US$15 million, excluding any exercise of the underwriter's option to purchase up to an additional 360,000 shares. Joseph Gunnar & Co. LLC is acting as sole book-running manager for the offering, with trading on Nasdaq expected to begin May 20, 2026, under the symbol OPTH.
The company stated it intends to use the net proceeds to scale production and distribution of its psychedelic drug products, support market expansion including into the United States, and fund sales growth, working capital and operating expenses. Optimi also confirmed the effectiveness of its previously announced 1-for-30 share consolidation, resulting in approximately 3.2 million common shares outstanding prior to the offering, subject to rounding and any additional issuances.
This move marks a significant milestone for Optimi, as the Nasdaq uplisting provides access to a broader investor base and increased visibility in the capital markets. The funds raised will be critical for the company to ramp up manufacturing capacity and pursue regulatory approvals in new jurisdictions. Optimi is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.
The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country's Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. The expansion into the U.S. market represents a key strategic objective, as the regulatory landscape for psychedelic-assisted therapies continues to evolve.
With the additional capital, Optimi is well-positioned to capture a growing share of the mental health treatment market, which is increasingly exploring psychedelic compounds for conditions such as PTSD, depression, and anxiety. The successful completion of the offering and Nasdaq uplisting could pave the way for further institutional investment and partnerships. For more information, visit the company's website at https://www.optimi.net/.
The full press release is available at https://ibn.fm/iwNJ5.